RecruitingPhase 1NCT07728487

Study of AT-587 in Healthy Subjects

A Phase 1, First-in-Human (FIH), Single-center, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of AT-587 in Healthy Adult Participants

Sponsor

Atea Pharmaceuticals, Inc.

Enrollment

62 participants

Start Date

Jul 13, 2026

Study Type

INTERVENTIONAL

Conditions

Hepatitis E

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-587 in healthy subjects

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AT-587 and Placebo for people with hepatitis e. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.